BIOTIME INC
S-8, 1997-07-02
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: DREYFUS MIDCAP INDEX FUND, 497, 1997-07-02
Next: TECHNOLOGY SOLUTIONS COMPANY, 8-K, 1997-07-02




      As filed with the Securities and Exchange Commission on July 2, 1997
                              Registration No. 333-
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                         -------------------------------

                                    FORM S-8
                             REGISTRATION STATEMENT
                                      UNDER
                           The Securities Act of 1933
                       ----------------------------------

                                  BIOTIME, INC.
               (Exact name of Registrant as specified in charter)
              ----------------------------------------------------

             California                                 94-3127919
   (State or other jurisdiction of                   (I.R.S. Employer
   incorporation or organization)                  Identification Number)
                           ---------------------------

                 935 Pardee Street
               Berkeley, California                        94710
(Address of Registrant's principal executive offices)    (Zip Code)

                            Paul E. Segall, President
                                  BioTime, Inc.
                                935 Pardee Street
                           Berkeley, California 94710
                     (Name and address of agent for service)

                                 (510) 845-9535
          (Telephone number, including area code, of agent for service)

                            -------------------------
   Copies of all communications,  including all communications sent to the agent
for service, should be sent to:

                             RICHARD S. SOROKO, ESQ.
                   Lippenberger, Thompson, Welch & Soroko LLP
                        250 Montgomery Street, Suite 500
                         San Francisco, California 94104
                               Tel. (415) 421-5300
                            -------------------------

<TABLE>
                                                   CALCULATION OF REGISTRATION FEE
<CAPTION>
                                                                                                      Proposed
                                                               Amount             Proposed             Maximum          Amount of
                                                                to be         Maximum Offering        Aggregate       Registration
   Title of Each Class of Securities to be Registered        Registered        Price Per Unit      Offering Price          Fee
                                                                                     (1)
 -----------------------------------------------------       ----------       ----------------     --------------     -------------
<S>                                                          <C>                <C>                  <C>               <C>
Options to Purchase Common Shares, no par value               200,000              $32.25             $6,450,000        $1,954.55
Common Shares, no par value(2)                                200,000              $32.25             $6,450,000           $0
Total Registration Fee..................................................................................................$1,954.55
=========================================================
<FN>
(1) Estimated solely for the purpose of calculating the registration  fee, based
upon the average bid and asked prices of the Common Shares on NASDAQ on June 26,
1997.

(2) Issuable upon exercise of the Options.

     Also  registered  hereunder  are an  indeterminate  number of Common Shares
which  may  be  issued  pursuant  to  antidilutive  provisions  of  the  Options
registered hereunder.
</FN>
</TABLE>
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------


<PAGE>



                                     PART II


               INFORMATION REQUIRED IN THE REGISTRATION STATEMENT


Item 3.  Incorporation of Documents By Reference.

     The contents of Registration  Statements on Form S-8, File Numbers 33-56766
and 33-88968  filed with the  Securities  and Exchange  Commission on January 5,
1993 and January 31, 1995, resepctively, are incorporated by reference.

Item 4.  Description of Securities.

          Options to Purchase Common Shares

          This  Registration  Statement  pertains to options to purchase 200,000
shares of the Registrant's  Common Shares,  no par value (the "Options"),  which
may be granted from time to time under the Registrant's  1992 Stock Option Plan,
as amended (the "Plan").  Under the Plan, the  Registrant  has reserved  600,000
Common Shares for issuance under Options granted to eligible persons.

          The  Registrant  has granted  383,000  Options as of June 1, 1997,  of
which 103,000 have been exercised and 280,000 remain outstanding.



                                      II-1

<PAGE>



Item 8.  Exhibits.

      Exhibit
      Number                        Description of Exhibits
      -------                       -----------------------

       4.1                    1992 Stock Option Plan, as amended*

       5                      Opinion of Counsel.*

      23.1                    Consent of Deloitte & Touche LLP*

      23.2                    Consent of Counsel is contained in the Opinion of 
                              Counsel, filed as a part hereof as Exhibit 5.*

      25                      Power of Attorney (See Page II-3)


- -------------------------
* Filed herewith.



                                      II-2

<PAGE>



                                   SIGNATURES

     Pursuant to the  requirements of the Securities Act of 1933, the Registrant
certifies  that is has  reasonable  grounds to believe  that it meets all of the
requirements  for  filing  on Form S-8 and has  duly  caused  this  Registration
Statement  to be  signed  on its  behalf  by  the  undersigned,  thereunto  duly
authorized, in the City of Berkeley, State of California on July 1, 1997.


                                                  BIOTIME, INC.


                                      By:
                                           --------------------------
                                           Paul E. Segall, President


                                POWER OF ATTORNEY

     Each person whose signature  appears below hereby authorizes Paul E. Segall
and Ronald S. Barkin, and each of them, as  attorneys-in-fact  and agents,  with
full powers of substitution,  to sign on his or her behalf,  individually and in
the  capacities  stated  below,  and to file any and all  amendments,  including
post-effective  amendments,  to this Registration Statement, and other documents
in connection therewith,  with the Securities and Exchange Commission,  granting
to said  attorneys-in-fact  and agents full power and  authority  to perform any
other act on behalf of the undersigned required to be done in the premises.

     Pursuant  to  the   requirements  of  the  Securities  Act  of  1933,  this
Registration  Statement  has been signed below by the  following  persons in the
capacities and on the dates indicated.



   Signature                       Title                          Date
   ----------                      ------                        ------


  s/Paul E. Segall           President and Director            July 1, 1997
 -------------------         (Principal Executive Officer)
  PAUL E. SEGALL


  s/Ronald S. Barkin         Executive Vice President and      July 1, 1997
  -------------------        Director
  RONALD S. BARKIN


  s/Harold Waitz             Vice President and Director       July 1, 1997
  -------------------
  HAROLD WAITZ


  s/Hal Sternberg            Vice President and Director       July 1, 1997
  -------------------
  HAL STERNBERG


                                      II-3

<PAGE>


   Signature                        Title                          Date
   ----------                       ------                        ------


  s/Victoria Bellport         Vice President, Chief            July 1, 1997
 --------------------         Financial Officer and 
  VICTORIA BELLPORT           Director (Principal Financial
                              and Accounting Officer)


                              Director                         July 1, 1997
 --------------------
  JEFFREY D. NICKEL


  s/Judith Segall             Vice President, Secretary        July 1, 1997
  -------------------         and Director
  JUDITH SEGALL



                                      II-4

<PAGE>



                                  EXHIBIT INDEX

      Exhibit
      Number                       Description of Exhibits
      -------                      -----------------------

       4.1                    1992 Stock Option Plan, as amended*

       5                      Opinion of Counsel.*

      23.1                    Consent of Deloitte & Touche LLP*

      23.2                    Consent of Counsel is contained in
                              the Opinion of Counsel, filed as a part
                              hereof as Exhibit 5.*

       25                     Power of Attorney (See Page II-3)


- -------------------------
* Filed herewith.





                                                                 Exhibit 4.1

                                  BIOTIME, INC.
                             1992 STOCK OPTION PLAN
                                  (as amended)


                                    ARTICLE I

                                     GENERAL

         1.       PURPOSE

         This  BioTime,  Inc. 1992 Stock Option Plan (the "Plan") is intended to
increase  incentive and to encourage stock ownership on the part of selected key
employees,  consultants,  professionals,  and members of the scientific advisory
board of BioTime, Inc. (the "Company"),  and other individuals whose efforts may
aid the Company, other corporations which may become subsidiaries or a parent of
the Company.  Except where the context obviously requires otherwise,  as used in
this Plan, the term "Company" includes BioTime, Inc. and any corporation that is
or becomes a parent or  subsidiary,  as defined in Section  425 of the  Internal
Revenue Code of 1986, as amended (the "Code"),  of BioTime,  Inc. It is also the
purpose  of  the  Plan  to  provide  such  employees,   consultants,  and  other
individuals  with a  proprietary  interest,  or to  increase  their  proprietary
interest,  in the Company and to  encourage  them to remain in the employ of the
Company or to continue to provide consulting, professional, or advisory services
to the Company. It is intended that certain options granted pursuant to the Plan
shall constitute incentive stock options within the meaning of Section 422(b) of
the Code and that certain other options  granted  pursuant to the Plan shall not
constitute incentive stock options ("nonqualified stock options").

         2.       ADMINISTRATION

         The Plan shall be administered by the Company's Board of Directors (the
"Board") or, in the discretion of the Board, by a committee (the "Committee") of
not less than two members of the Board; provided, that options may be granted to
officers and  directors of the  corporation  only by the Board or by a Committee
all of the members of which are "Non-Employee Directors" as such term is defined
in paragraph  (b)(3)(i) of Rule 16b-3 promulgated under the Securities  Exchange
Act of 1934.  No member of the  Committee  shall grant to himself or herself any
options under the Plan or options,  stock or stock appreciation rights under any
other stock  option or stock bonus plan of the Company or any of its  affiliates
while serving on the Committee. The Committee's  interpretation and construction
of any term or  provision  of the Plan or of any option  granted  under the Plan
shall be final,  unless  otherwise  determined by the Board, in which event such
determination  by the Board shall be final.  The Board or the Committee may from
time to time adopt rules and regulations for carrying out this Plan and, subject
to the  provisions  of  this  Plan,  may  prescribe  the  form or  forms  of the
instruments evidencing any option granted under this


                                        1

<PAGE>



Plan. No member of the Board or the Committee  shall be liable for any action or
determination  made in good faith with respect to the Plan or any option granted
under the Plan.

         Subject to the provisions of this Plan, the Board or the Committee,  by
delegation from the Board, shall have full and final authority in its discretion
to select  the  eligible  persons to whom  options  are  granted,  to grant such
options  and to  determine  the  number  of shares to be  subject  thereto,  the
exercise  prices,  the terms of exercise,  expiration  dates and other pertinent
provisions of such options. The Board may delegate to the Committee the power to
make all  determinations  with  respect  to the  Plan,  or may  delegate  to the
Committee  only  certain  aspects  of Plan  administration,  such  as  selecting
officers and directors for  participation  and decisions  concerning the timing,
pricing, and amount of a grant or award of options.

         3.       ELIGIBILITY.

         Subject  to  Section  2 of this  Article  I, the  persons  who shall be
eligible  to  receive  options  under the Plan  shall be such  officers  and key
employees  (including  directors who are also salaried employees of the Company)
of the Company as the Board (or the  Committee if designated by the Board) shall
select. In addition, directors, consultants,  professionals (such as accountants
and  lawyers),   members  of  the  Company's   scientific  advisory  board,  and
independent  contractors  of the Company who are not also salaried  employees of
the Company  shall be eligible to receive  nonqualified  stock options (but such
persons shall not be eligible to receive  incentive  stock  options).  The terms
"officers and key employees" as used herein shall mean such key employees as may
be  determined by the Board (or the Committee if designated by the Board) in its
sole discretion.

         4.       SHARES OF STOCK SUBJECT TO THE PLAN.

         The shares that may be issued  under the Plan shall be  authorized  and
unissued or reacquired Common Shares of the Company (the "Common  Shares").  The
aggregate  number of shares  which may be issued under the Plan shall not exceed
600,000  Common  Shares,  unless an adjustment  is required in  accordance  with
Article III.

         5.       AMENDMENT OF THE PLAN.

         The Board may, insofar as permitted by law, from time to time,  suspend
or discontinue the Plan or revise or amend it in any respect whatsoever,  except
that no such  amendment  shall  alter  or  impair  or  diminish  any  rights  or
obligations  under any option  theretofore  granted under the Plan,  without the
consent of the person to whom such option was granted, except as permitted under
Section 8 of this Article I. In addition,  without further shareholder approval,
no such  amendment  shall  increase  the  number of shares  subject  to the Plan
(except as authorized by Article III),  change the  designation  in Section 3 of
Article I of the class of persons  eligible to receive  options  under the Plan,
extend the term during which options may be exercised,  or extend the final date
upon which options under the Plan may be granted.


                                        2

<PAGE>



         6.       APPROVAL OF SHAREHOLDERS.

         All  options  granted  under the Plan  before the Plan is  approved  by
affirmative  vote of the holders of a majority of the Common Shares  present and
eligible to vote at the next  meeting of  shareholders  of the  Company,  or any
adjournment  thereof,  shall be  subject  to such  approval.  No option  granted
hereunder may become exercisable unless and until such approval is obtained.

         7.       TERM OF PLAN.

         Options may be granted under the Plan until June 30, 2002,  the date of
termination  of the Plan.  Notwithstanding  the  foregoing,  each option granted
under the Plan shall  remain in effect  until such option has been  exercised or
terminated in accordance with its terms and the terms of the Plan.

         8.       LISTING, REGISTRATION, QUALIFICATION, AND CONSENTS.

         All options  granted under the Plan shall be subject to the requirement
that,  if at any  time  the  Board  or the  Committee  shall  determine,  in its
discretion,  that the  listing,  registration  or  qualification  of the  shares
subject to options granted under the Plan, upon any securities exchange or under
any  state  or  federal  law,  or the  consent  or  approval  of any  government
regulatory  body,  is necessary or desirable as a condition of, or in connection
with, the granting of such option or the issuance, if any, or purchase of shares
in  connection  therewith,  such option may not be exercised in whole or in part
unless such listing, registration, qualification, consent or approval shall have
been effected or obtained free of any  conditions not acceptable to the Board or
the Committee.  Furthermore,  if the Board or the Committee  determines that any
amendment  to any option  (including,  but not  limited  to, an  increase in the
exercise price) is necessary or desirable in connection with the registration or
qualification of any of its shares under any state securities or "blue sky" law,
then the Board or the  Committee  shall have the  unilateral  right to make such
changes without the consent of the optionee.

         9.       NONASSIGNABILITY.

         No option shall be assignable or  transferable by the grantee except by
will or by the laws of descent  and  distribution,  or  pursuant  to a qualified
domestic  relations  order as  defined  by the  Code or Title I of the  Employee
Retirement  Income  Security Act or the rules  thereunder;  provided,  that,  to
facilitate the optionee's  financing of the exercise of an option,  the Board or
Committee may permit the  assignment of an option to a  broker-dealer  that is a
member of the National  Association of Securities  Dealers if such broker-dealer
acquires  such  option for the  purpose of  immediate  exercise  and sale of the
underlying Common Shares. During the lifetime of the optionee,  the option shall
be  exercisable  only by the  optionee,  and no other person  shall  acquire any
rights therein,  except as permitted by the preceding sentence.  The designation
of a beneficiary by an optionee does not constitute transfer.



                                        3

<PAGE>



         10.      WITHHOLDING TAXES.

         Whenever Common Shares are to be issued upon the exercise of any option
under the Plan,  the  Company  shall have the right to require  the  optionee to
remit to the Company an amount  sufficient to satisfy federal,  state, and local
withholding  tax  requirements  prior  to the  delivery  of any  certificate  or
certificates for such shares.

         11.      DEFINITION OF "FAIR MARKET VALUE".

         For the purposes of this Plan,  the term "fair market value," when used
in  reference  to the date of grant of an  option  or the date of  surrender  of
Common Shares in payment for the purchase of shares  pursuant to the exercise of
any option, as the case may be, shall mean the amount determined by the Board or
the Committee as follows:

         (a) If the shares are listed or have unlisted  trading  privileges on a
national  securities  exchange,  the  shares  shall be valued at their last sale
price on the  principal  national  securities  exchange  (measured  by volume of
transactions in such shares) on which such securities shall have traded,  or, if
available,  such sales  price as  reported on the  composite  tape,  on the last
trading day immediately preceding the date of grant or surrender.

         (b) If the shares are  included in the  National  Market  System of the
Nasdaq Stock Market,  the shares shall be valued at their last sale price on the
last  trading  day  immediately  preceding  the date of grant  or  surrender  as
reported in the price  quotations  for the  National  Market  System in The Wall
Street Journal, if such a trade occurs.

         (c) If the shares are described in either subparagraph (a) or (b) above
but were not traded on the last trading day  immediately  preceding  the date of
grant or  surrender,  or if prices of the shares are quoted in the Nasdaq  Stock
Market  (but not the  National  Market  System),  or if prices of the shares are
published  by the  National  Quotation  Bureau,  Inc.,  then the shares shall be
valued at the last sale price on the last trading day immediately  preceding the
date of grant or  surrender  as reported in The Wall Street  Journal,  if such a
trade occurs;  or if no such trade occurs,  the average of the last bid and last
asked  prices  reported in the Wall Street  Journal or published by the National
Quotation Bureau within the 30 days prior to the date of grant or surrender.

         (d) If the shares are not  described in and valued under  subparagraphs
(a),  (b) or (c)  above,  then the  shares  shall be  valued by the Board or the
Committee, in its sole judgement, in good faith.

         (e) If the  shares  are  listed  or  traded  on a  national  securities
exchange and are included in the Nasdaq Stock Market (whether or not included in
the  National  Market  System),  the  Board or the  Committee  may,  in its sole
judgment and good faith,  determine to value the shares under subparagraphs (a),
(b) or (c).



                                        4

<PAGE>



                                   ARTICLE II

                                  STOCK OPTIONS


         1.       AWARD OF STOCK OPTIONS.

         Awards of stock  options may be made under the Plan under all the terms
and  conditions  contained  herein.  However,  in the  case of  incentive  stock
options,  the aggregate fair market value (determined as of the date of grant of
the option) of the Common Shares with respect to which  incentive  stock options
are  exercisable  for the first time by such officer or key employee  during any
calendar year (under all incentive  stock option plans of the Company) shall not
exceed  $100,000.  The date on which any option is granted  shall be the date of
the Board's or the Committee's authorization of such grant or such later date as
may be  determined  by the  Board or the  Committee  at the time  such  grant is
authorized.

         2.       TERM OF OPTIONS AND EFFECT OF TERMINATION.

         Notwithstanding any other provision of the Plan, an option shall not be
exercisable  after the  expiration of ten (10) years from the date of its grant.
In addition, notwithstanding any other provision of the Plan, no incentive stock
option  granted  under  the Plan to a person  who,  at the time  such  option is
granted,  owns stock possessing more than 10% of the total combined voting power
of  all  classes  of  stock  of  the  Company  or of any  parent  or  subsidiary
corporation,  shall be  exercisable  after the expiration of five (5) years from
the date of its grant.

         In the event  that any  outstanding  option  under the Plan  expires by
reason of lapse of time or otherwise is  terminated  or canceled for any reason,
then the Common  Shares  subject to any such  option  which have not been issued
pursuant to the exercise of the option shall again become  available in the pool
of Common Shares for which options may be granted under the Plan.

         3.       CANCELLATION OF AND SUBSTITUTION FOR OPTIONS.

         The  Company  shall  have the  right to cancel  any  option at any time
before it  otherwise  would  have  expired by its terms and to grant to the same
optionee in  substitution  therefor a new stock  option  stating an option price
which is lower (but not higher)  than the option  price  stated in the  canceled
option.  Any such substituted  option shall contain all the terms and conditions
of the canceled option  provided,  however,  that  notwithstanding  Section 2 of
Article  II,  such  substituted  option  shall  not  be  exercisable  after  the
expiration of ten (10) years from the date of grant of the canceled option.



                                        5

<PAGE>



         4.       TERMS AND CONDITIONS OF OPTIONS.

         Options  granted  pursuant to the Plan shall be evidenced by agreements
in such form as the Board or the  Committee  shall from time to time  determine,
which agreements shall comply with the following terms and conditions.

                  (A)      Number of Shares and Type of Option

                  Each option  agreement shall state the number of Common Shares
for which the option is exercisable  and whether the option is intended to be an
incentive stock option or a nonqualified stock option.

                  (B)      Option Price

                  Each option agreement shall state the exercise price per share
or the method by which such price  shall be  computed.  The  exercise  price per
share shall be  determined by the Board or the Committee at the date such option
is granted. In the case of a nonqualified  option, the exercise price may be not
less than 85% of the fair  market  value of the  Common  Shares on the date such
option is granted.  In the case of an incentive stock option, the exercise price
shall be not less than 100% of the fair market value of the Common Shares on the
date such option is granted.  Notwithstanding the foregoing,  the exercise price
per share of a option  granted to a person who, on the date of such grant and in
accordance with Section 425(d) of the Code, owns stock  possessing more than 10%
of the total combined  voting power of all classes of stock of the Company or of
any parent or  subsidiary  corporation,  shall be not less than 110% of the fair
market value of the Common Shares on the date that the option is granted.

                  (C)      Medium and Time of Payment

                  The  exercise  price shall be payable  upon the exercise of an
option  in the  lawful  currency  of the  United  States of  America  or, in the
discretion of the Board or the  Committee,  in Common Shares or in a combination
of such  currency and such shares.  Upon receipt of payment,  the Company  shall
deliver  to  the  optionee  (or  person  entitled  to  exercise  the  option)  a
certificate  or  certificates  for the  Common  Shares  purchased  through  such
exercise.

                  (D)      Exercise of Options

                  Each  option  shall  state the time or times  when it  becomes
exercisable,  which shall be determined by the Board or the Committee; provided,
that all  options  shall  vest at a rate not less than 20% per year over 5 years
from the date of grant.

         To the extent that an option has become  vested  (except as provided in
Article III), and subject to the foregoing restrictions,  it may be exercised in
whole or in such lesser amount as may


                                        6

<PAGE>



be authorized by the option  agreement.  If exercised in part,  the  unexercised
portion  of an  option  shall  continue  to be  held  by the  optionee  and  may
thereafter be exercised as herein provided.

                  (E)    Termination of Employment Except By Disability or Death

         In the event that an optionee  who is an employee of the Company  shall
cease to be employed  by the Company for any reason  other than his or her death
or  disability,  his or her option shall  terminate on the date (3) months after
the date that he ceases to be an employee of the Company.  The  Committee or the
Board may waive the provisions of this  Subsection  4(E) at the date of grant of
an option or at a later date.

                  (F)      Disability of Optionee

                  If an optionee  who is an employee of the Company  shall cease
to be employed by the Company by reason of his or her becoming  permanently  and
totally  disabled  within  the  meaning  of  Section  22(e)(3)  of the  Code (as
determined by the Board or the  Committee),  such option shall  terminate on the
date one (1) year after  cessation of  employment  due to such  disability.  The
Committee or the Board may waive the provisions of this  Subsection  4(F) at the
time of grant of an option or at a later date if the option is not an  incentive
stock option.

                  (G)      Death of Optionee and Transfer of Option

                  If an optionee  should die while in the employ of the Company,
or within the three-month period after termination of his or her employment with
the  Company  during  which he or she is  permitted  to  exercise  an  option in
accordance  with Subsection 4(F) of this Article II, such option shall terminate
on the date one (1) year  after  the  optionee's  death.  During  such  one-year
period,  such option may be exercised by the executors or  administrators of the
optionee's estate or by any person or persons who shall have acquired the option
directly from the optionee by his or her will or the  applicable  law of descent
and distribution. During such one year period, such option may be exercised with
respect to the number of shares for which the deceased  optionee would have been
entitled to exercise it at the time of his or her death.  The  Committee  or the
Board may waive the provisions of this  Subsection  4(G) at the date of grant of
an option or at a later date if the option is not an incentive stock option.


                                   ARTICLE III

                      RECAPITALIZATIONS AND REORGANIZATIONS

         The  number of Common  Shares  covered  by the Plan,  and the number of
Common  Shares  and  price  per  share  of each  outstanding  option,  shall  be
proportionately  adjusted  for any  increase or decrease in the number of issued
and outstanding  Common Shares  resulting from a subdivision or consolidation of
shares or the payment of a stock dividend, or any other increase or decrease


                                        7

<PAGE>



in the number of issued and outstanding  Common Shares effected  without receipt
of consideration by the Company.

         Upon  the  dissolution  or  liquidation  of  the  Company,  or  upon  a
reorganization,  merger or consolidation of the Company as a result of which the
outstanding  securities  of the class  then  subject to  options  hereunder  are
changed  into  or  exchanged  for  cash or  property  or  securities  not of the
Company's issue, or upon a sale of substantially all the property of the Company
to, or the acquisition of stock  representing  more than eighty percent (80%) of
the  voting  power of the stock of the  Company  then  outstanding  by,  another
corporation or person,  the Plan shall  terminate,  and all options  theretofore
granted  hereunder shall  terminate,  unless provision can be made in writing in
connection with such  transaction for the continuance of the Plan and/or for the
assumption of options theretofore  granted, or the substitution for such options
of  options  covering  the stock of a  successor  corporation,  or a parent or a
subsidiary  thereof,  with appropriate  adjustments as to the number and kind of
shares and prices, in which event the Plan and options theretofore granted shall
continue in the manner and under the terms so provided.

         To the  extent  that  the  foregoing  adjustments  relate  to  stock or
securities of the Company,  such adjustments  shall be made by the Board,  whose
determination in that respect shall be final, binding and conclusive.

         The grant of an option pursuant to the Plan shall not affect in any way
the  right or  power  of the  Company  to make  adjustments,  reclassifications,
reorganizations  or changes or its capital or business  structure or to merge or
to consolidate or to dissolve, liquidate or sell, or transfer all or any part of
its business or assets.


                                   ARTICLE IV

                            MISCELLANEOUS PROVISIONS

         1.       RIGHTS AS A SHAREHOLDER.

         An  optionee  or a  transferee  of an option  shall have no rights as a
shareholder  with  respect to any Common  Shares  covered by an option until the
date of the receipt of payment  (including  any amounts  required by the Company
pursuant to Section 10 of Article I) by the Company. No adjustment shall be made
as to any option for  dividends  (ordinary  or  extraordinary,  whether in cash,
securities  or other  property) or  distributions  or other rights for which the
record date is prior to such date, except as provided in Article III.

         2.       MODIFICATION, EXTENSION AND RENEWAL OF OPTIONS

         Subject to the terms and conditions  and within the  limitations of the
Plan,  the  Board  or  the  Committee  may  modify,  extend,  renew,  or  cancel
outstanding options granted under the Plan.


                                        8

<PAGE>



Notwithstanding  the foregoing,  however,  no  modification  of an option shall,
without the consent of the optionee impair or diminish any rights or obligations
under any option  theretofore  granted  under the Plan,  except as  provided  in
Section 8 of Article I. For purposes of the preceding sentence, the right of the
Company pursuant to Section 3 of Article II to cancel any outstanding option and
to issue theretofor a substituted  option stating a lower option price shall not
be construed as impairing or diminishing an optionee's rights or obligations.

         3.       OTHER PROVISIONS.

         The option  agreements  authorized  under the Plan shall  contain  such
other provisions, including, without limitation,  restrictions upon the exercise
of the option or restrictions required by any applicable securities laws, as the
Board or the Committee shall deem advisable.

         4.       APPLICATION OF FUNDS.

         The  proceeds  received by the Company  from the sale of Common  Shares
pursuant to the exercise of options will be used for general corporate purposes.

         5.       NO OBLIGATION TO EXERCISE OPTION.

         The granting of an option shall impose no obligation  upon the optionee
or a transferee of the option to exercise such option.

         6.       FINANCIAL ASSISTANCE.

         The  Company  is vested  with  authority  under this Plan to assist any
employe  to whom an option is  granted  hereunder  (including  any  director  or
officer of the Company or any of its  subsidiaries  who is also an  employee) in
the payment of the purchase price payable on exercise of that option, by lending
the amount of such  purchase  price to such  employee  on such terms and at such
rates of  interest  and upon such  security  (or  unsecured)  as shall have been
authorized by or under authority of the Board or the Committee.

         7.       FINANCIAL REPORTS.

         The Company  shall deliver to each grantee of an option a balance sheet
of the Company as at the end of its most recently  completed fiscal year, and an
income  statement  of the  Company  as of the  end of  such  fiscal  year.  Such
financial  statements  shall be  delivered  no less  frequently  than  annually;
provided,  that such financial  statements need not be delivered to any employee
whose duties as an employee assure them access to such financial information.


                                        9



                                                                  Exhibit 5

                                   LAW OFFICES
                   LIPPENBERGER, THOMPSON, WELCH & SOROKO LLP
                              250 MONTGOMERY STREET
                                    SUITE 500
                             SAN FRANCISCO, CA 94104

                                (415) 421-5300
                            FACSIMILE (415) 421-0225


                                        June 30, 1997


Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

         Re:      BioTime, Inc.
                  Registration Statement on Form S-8

Ladies/Gentlemen:

         We are counsel to BioTime,  Inc. (the "Company") in connection with the
offer and sale of up to 200,000 Common Shares (the  "Shares")  issuable upon the
exercise of a like number of options  (the  "Options")  that may be granted from
time to time  under the  Company's  1992 Stock  Option  Plan,  as  amended  (the
"Plan").  The offer and sale of the Options and Shares is being registered under
the Securities Act of 1933, as amended,  pursuant to a Registration Statement on
Form S-8.

         We are of the opinion that when the Options are granted under the terms
and  provisions of the Plan,  the Options will be the legally and validly issued
and  outstanding  and  will  constitute  binding  obligations  of  the  Company,
enforceable in accordance with their terms. We are also of the opinion that when
the Shares are issued and sold upon the exercise of the Options,  in  accordance
with the terms and  provisions  of the Options and the Plan,  the Shares will be
legally and validly issued and outstanding, fully paid and nonassessable.

         The foregoing opinion is limited to the laws of the State of California
and the Federal laws of the United States of America.

         We  hereby  consent  to  the  use of our  opinion  in the  Registration
Statement.


                                      Very truly yours,


                                      Lippenberger, Thompson, Welch & Soroko LLP





                         INDEPENDENT AUDITORS' CONSENT



We consent to the incorporation by reference in this  Registration  Statement of
BioTime,  Inc.  on Form S-8 of our report  dated  August 8, 1996  (which  report
expresses an unqualified opinion and includes an explanatory paragraph referring
to the Company being in the development  stage),  appearing in the Annual Report
on Form 10-K of BioTime, Inc. for the year ended June 30, 1996.




DELOITTE & TOUCHE LLP
San Jose, California
July 1, 1997


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission